No Data
No Data
No Data
No Data
No Data
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation Co
Vor BiopharmaMay 3 12:00
Vor Biopharma Welcomes Oncology Expert to Board of Directors
TipRanksMay 3 04:27
Press Release: Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to Its Board of Directors
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR),
Dow JonesMay 3 04:01
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to Its Board of Directors
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board o
Vor BiopharmaMay 2 12:00
Wedbush: The Vor Biopharma (VOR.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $11.00.
Wedbush: The Vor Biopharma (VOR.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $11.00.
Zhitong FinanceApr 24 01:30
Wedbush Reiterates Outperform on Vor Biopharma, Maintains $11 Price Target
Wedbush analyst David Nierengarten reiterates Vor Biopharma (NASDAQ:VOR) with a Outperform and maintains $11 price target.
BenzingaApr 24 01:24
No Data
No Data